Intervention

Envafolimab

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting1

Common conditions10

Lead sponsors shown7

Clinical trials

8 shown

RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment FailureNCT06663007 · 2024-09-24

SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLCNCT07818304 · 2026-10-01

NOT_YET_RECRUITING

Local Injection and Systemic Therapy in the Treatment of NSCLC.NCT06618391 · 2024-10-08

NOT_YET_RECRUITING

YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic SarcomaNCT05448820 · 2022-11-14

A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung CancerNCT05414630 · 2022-06-01

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLCNCT05203276 · 2022-03-01

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.NCT05068427 · 2021-11-23

Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLCNCT05055167 · 2021-08-30

Common conditions

Lung Neoplasms2 Non Small Cell Lung Cancer2 Advanced Sarcoma1 CDK12 Gene Mutation1 Metastatic Sarcoma1 Non-small Cell Lung Cancer1 Non-small Cell Lung Cancer Stage III1 Non-small Cell Lung Cancer Stage IV1 Prostate Cancer1 Soft Tissue Sarcoma1

Leading sponsors

The First People's Hospital of Lianyungang2 Anhui Provincial Cancer Hospital1 Chipscreen Biosciences, Ltd.1 Henan Cancer Hospital1 The First Affiliated Hospital of Xiamen University1 Tianjin Medical University Second Hospital1 Tracon Pharmaceuticals Inc.1

Trial status mix

UNKNOWN4

NOT_YET_RECRUITING2

COMPLETED1

RECRUITING1

Phase mix

PHASE28

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.